TREATMENT PATTERNS OF ADVANCED EGFR-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) IN LATIN AMERICA

被引：0
|
作者：
Alves, J. S. [1 ]
Watanabe de Oliveira, R. [1 ]
Oliveira, D. [2 ]
Medina, Y. [3 ]
Osorio, M. [4 ]
Tabares, M. [5 ]
Tamayo, C. [6 ]
Kano, B. [7 ]
Muller Bernz, I [7 ]
机构：
[1] Janssen Cilag Farmaceut Ltda, Sao Paulo, Brazil
[2] Johnson & Johnson Med Brazil, Sao Paulo, Brazil
[3] Johnson & Johnson, Janssen Pharmaceut Co, Bogota, Cun, Colombia
[4] IQVIA, Mexico City, DF, Mexico
[5] IQVIA, Buenos Aires, DF, Argentina
[6] IQVIA, Bogota, Cun, Colombia
[7] IQVIA, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA56
引用
收藏
页码：S552 / S552
页数：1
相关论文
共 50 条
  • [31] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    LUNG CANCER, 2002, 38 : S47 - S50
  • [32] Squamous, non-small Lung Cancer (NSCLC) Necitumumab: Significant Survival Advantage for EGFR-positive, Chemotherapy-naive Patients
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (06) : 405 - 405
  • [33] Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding
    Passaro, Antonio
    Gianoncelli, Letizia
    Stati, Valeria
    de Marinis, Filippo
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [34] Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
    Passaro, Antonio
    de Marinis, Filippo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S334 - S338
  • [35] Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
    Cucchiara, Federico
    Del Re, Marzia
    Valleggi, Simona
    Romei, Chiara
    Petrini, Iacopo
    Lucchesi, Maurizio
    Crucitta, Stefania
    Rofi, Eleonora
    De Liperi, Annalisa
    Chella, Antonio
    Russo, Antonio
    Danesi, Romano
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [36] A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)
    Li, J.
    Ge, J.
    Tian, Y.
    Yang, Y.
    Zheng, M.
    Yu, P.
    Yao, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S602 - S602
  • [37] Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta
    Cheung, Winson Y.
    Carbonell, Chantelle
    Navani, Vishal
    Sangha, Randeep S.
    Ewara, Emmanuel M.
    Elia-Pacitti, Julia
    Iczkovitz, Sandra
    Jarada, Tamer N.
    Warkentin, Matthew T.
    CURRENT ONCOLOGY, 2024, 31 (08) : 4382 - 4396
  • [38] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Effect of Antibiotic Exposure on the Efficacy of EGFR TKIs in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
    Pengnoraphat, B.
    Saichaemchan, S.
    Thambamroong, T.
    Phavirunsiri, J.
    Peechatanan, K.
    Prasongsook, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S623 - S623
  • [40] Impact of Patient TKI Copayments on Insurance Expenditure in Advanced EGFR or ALK Positive Non-Small Cell Lung Cancer (NSCLC)
    Goulart, B. Haddock Lobo
    Chennupati, S.
    Egan, K.
    Fedorenko, C.
    Ramsey, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S599 - S599
12345